Other Name(s):

Corpus Luteum Hormone, Hormone de Grossesse, Hormone du Corps Jaune, Hormone Lutéale, Hormone Progestative, Luteal Hormone, Luteohormone, Lutine, NSC-9704, Pregnancy Hormone, Pregnanedione, Prégnanedione, Progestational Hormone, Progesterona, Progestérone, Progesteronum, 4-Pregnene-3; 20-Dione.


Progesterone is a hormone that occurs naturally in the body. It can also be made in a laboratory.

"Progestin" is a general term for a substance that causes some or all of the biologic effects of progesterone. The term "progestin" is sometimes used to refer to the progesterone made in the laboratory that is in oral contraceptives and hormone replacement therapy. However, all progesterone and progestin products are made in the laboratory. The term "natural progesterone" is really a misnomer. "Natural progesterones," including the prescription products Crinone and Prometrium, are made from a chemical called diosgenin that is isolated from wild yam or soy. In the laboratory, this constituent is converted to pregnenolone and then to progesterone. The human body is not able to make progesterone from diosgenin, so eating wild yam or soy will not boost your progesterone levels.

Over-the-counter (OTC) progesterone products may not contain progesterone concentrations as labeled. According to a British report, two-ounce jars of Progest cream used in a clinical trial contained 100 mg progesterone per ounce rather than the 465 mg claimed by the manufacturer.

Topical progesterone products (preparations applied to the skin) marketed as cosmetics require no FDA approval prior to marketing. There is currently no limit on the amount of progesterone allowed in cosmetic products. In 1993 the FDA proposed a rule limiting progesterone-containing cosmetic products to a maximum level of 5 mg/oz with the product label instructing users not to exceed 2 oz per month. But this rule was never finalized.

Women take progesterone by mouth for inducing menstrual periods; and treating abnormal uterine bleeding associated with hormonal imbalance, and severe symptoms of premenstrual syndrome (PMS). Progesterone is also used in combination with the hormone estrogen to "oppose estrogen" as part of hormone replacement therapy. If estrogen is given without progesterone, estrogen increases the risk of uterine cancer.

Progesterone is also used to ease withdrawal symptoms when certain drugs (benzodiazepines) are discontinued.

Progesterone cream is sometimes used in hormone replacement therapy and for treating menopausal symptoms such as hot flashes. Topical progesterone is also used for treating or preventing certain allergies in which hormones play a role; and for treating bloating, breast tenderness, decreased sex drive, depression, fatigue, lumpy (fibrocystic) breasts, headaches, low blood sugar, increased blood clotting, infertility, irritability, memory loss, miscarriages, brittle bones (osteoporosis), bone loss in younger women, symptoms of PMS, thyroid problems, "foggy thinking," uterine cancer, uterine fibroids, water retention, weight gain, and vaginal irritation (vulval lichen sclerosis).

Progesterone gel is sometimes used inside the vagina to expand the cervix (cervical ripening), treat breast pain in women with noncancerous breast disease, and to prevent and treat abnormal thickening of the lining of the uterus (endometrial hyperplasia).

Progesterone is also used intravaginally or by injection for treating infertility and symptoms of (PMS).

How does it work?

Progesterone is a hormone released by the ovaries. Changing progesterone levels can contribute to abnormal menstrual periods and menopausal symptoms. Progesterone is also necessary for implantation of the fertilized egg in the uterus and for maintaining pregnancy.

Lab-made progesterone is used to imitate the functions of the progesterone released by the ovaries.

Uses & Effectiveness

Likely Effective for...

  • Absence of menstrual periods (amenorrhea). Taking progesterone by mouth and applying progesterone gel into the vagina are effective strategies for treating absence of menstrual periods in premenopausal women. Micronized progesterone is FDA-approved for this use, as is intravaginal progesterone gel (Crinone 4%).
  • Hormone replacement therapy (HRT). Micronized progesterone (Prometrium) is FDA-approved for use with estrogen as a component of HRT. Research shows that adding progesterone to HRT protects against side effects of estrogen.
  • Infertility. Intravaginal progesterone gel (Crinone 8%) is FDA-approved for use as a part of infertility treatment in women. Some research suggests that applying progesterone intravaginally and injecting it into the muscle may have similar effectiveness for increasing pregnancy rates as giving it by mouth. Also, research suggests that intravaginal progesterone seems to be as effective for pregnancy rates as human chorionic gonadotropin (HCG).

Possibly Effective for...

  • Abnormal thickening of the endometrium (endometrial hyperplasia). Some research suggests that applying progesterone (Crinone) into the vagina prevents endometrial hyperplasia in women with an intact uterus that are taking estrogen replacement therapy. Other early research shows that a specific intravaginal progesterone cream may help reverse abnormal thickening of the endometrium and decrease vaginal bleeding in premenopausal women with non-cancerous endometrial hyperplasia.
  • Breast pain (mastodynia). Some research suggests that applying progesterone (Crinone) into the vagina seems to reduce breast pain and tenderness in women with non-cancerous breast disease.
  • Menopausal symptoms. Some research suggests that applying a specific progesterone cream (Progest) to the skin reduces symptoms such as hot flashes in menopausal women.
  • Premature labor. Some research suggests that applying progesterone gel into the vagina, alone or along with therapy to delay labor (tocolytic therapy), reduces the risk of premature delivery in women at high risk of premature birth. However, other research suggests that intravaginal progesterone gel does not decrease the frequency of premature birth in women with a history of premature birth.

Possibly Ineffective for...

  • Withdrawal symptoms from drugs such as diazepam (Valium), alprazolam (Xanax), temazepam (Restoril), and others. Some research suggests that taking micronized progesterone by mouth may not be effective for relieving symptoms of withdrawal and for helping people to abstain from taking diazepam.
  • Miscarriage. Most research suggests that applying progesterone into the vagina does not reduce the risk of having a miscarriage during the first trimester in women at high risk for miscarriage. Also, injecting progesterone and another steroid hormone into the muscle after undergoing a test used to diagnose birth defects (called an amniocentesis) does not seem to reduce the risk of miscarriage or preterm delivery.
  • Premenstrual syndrome (PMS). Although some clinical research suggests that applying progesterone into the vagina or the rectum before menstruation reduces symptoms of PMS, most evidence shows that giving progesterone by mouth or rectally does not reduce PMS symptoms.
  • Vaginal irritation (vulval lichen sclerosis). Applying progesterone into the vagina does not seem to improve symptoms of vulval lichen sclerosis. In fact, progesterone seems to be less effective than clobetasol (Temovate) for treating this condition.

Insufficient Evidence to Rate Effectiveness for...

  • Heart disease. Early research suggests that applying progesterone into the vagina may increase exercise endurance compared to taking a similar steroidal drug (medroxyprogesterone) by mouth in women with heart disease or women that previously experienced a heart attack.
  • Cocaine dependence. Early research suggests that taking progesterone by mouth does not decrease the risk of cocaine use in methadone-stabilized male cocaine users.
  • Preventing bone loss (osteoporosis). Some research suggests that applying progesterone to the skin is not effective for increasing bone mineral density in postmenopausal women. Other research shows that applying progesterone to the skin for 2 years may be as effective for preventing bone loss as drinking isoflavone-containing soy milk. However, the combination of soy milk plus progesterone seems to result greater bone loss than either single treatment alone.
  • Depression after childbirth (postpartum). Early research suggests that applying progesterone into the rectum does not reduce symptoms of postpartum depression.
  • High blood pressure during pregnancy (pre-eclampsia). Early research suggests that single injections of progesterone reduce blood pressure, swelling, and other symptoms in women with pre-eclampsia.
  • Treating or preventing allergies affected by hormones.
  • Bloating.
  • Decreased sex drive.
  • Fatigue.
  • Headaches.
  • Low blood sugar (hypoglycemia).
  • Increased blood clotting.
  • Irritability.
  • Memory loss.
  • Thyroid problems.
  • "Foggy thinking".
  • Uterine cancer.
  • Uterine fibroids.
  • Water retention.
  • Weight gain.
  • Other conditions.
More evidence is needed to rate the effectiveness of progesterone for these uses.

Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).


If menopause occurs in a woman younger than ___ years, it is considered to be premature. See Answer

Side Effects

The progesterone prescription products that have been approved by the Food and Drug Administration (FDA) are LIKELY SAFE for most people when used by mouth, applied to the skin, applied into vagina, or injected into the muscle with the advice and care of a healthcare professional. However, progesterone can cause many side effects including stomach upset, changes in appetite, weight gain, fluid retention and swelling (edema), fatigue, acne, drowsiness or insomnia, allergic skin rashes, hives, fever, headache, depression, breast discomfort or enlargement, premenstrual syndrome (PMS)-like symptoms, altered menstrual cycles, irregular bleeding, and other side effects.

Special Precautions & Warnings

Pregnancy and breast-feeding: Intravaginal progesterone gel is LIKELY SAFE when used as part of infertility treatment. However, progesterone is LIKELY UNSAFE when used during pregnancy for any other purpose.

There is not enough reliable information about the safety of taking progesterone if you are breast-feeding. Stay on the safe side and avoid use.

Arterial disease: Don't use progesterone if you have arterial disease.

Breast cancer: Avoid use unless you are directed to do so by your healthcare provider.

Depression: Get your healthcare provider's advice first before using progesterone if you have major depression now or a history of major depression.

Liver disease: Progesterone might make liver disease worse. Don't use it.

Vaginal bleeding: If you have undiagnosed vaginal bleeding, don't use progesterone.


EstrogensInteraction Rating: Moderate Be cautious with this combination.Talk with your health provider.

Progesterone and estrogen are both hormones. They are often taken together. Progesterone can decrease some of the side effects of estrogen. But progesterone might also decrease the beneficial effects of estrogen. Taking progesterone along with estrogen might cause breast tenderness.

Some estrogen pills include conjugated equine estrogens (Premarin), ethinyl estradiol, estradiol, and others.

Paclitaxel (Abraxane, Onxol)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.

Injecting high-doses of progesterone intravenously (by IV) in combination with the drug paclitaxel might increase levels of paclitaxel in the blood. However, the combination does not seem to increase the side effects of paclitaxel. Until more is known, use progesterone cautiously or avoid using in patients being treated with paclitaxel.


The following doses have been studied in scientific research:


  • For hormone replacement therapy: 200 mg micronized progesterone (Prometrium) per day is typically taken for 12 days of a 25-day cycle with 0.625 mg conjugated estrogens.
  • For hot flashes and other symptoms of menopause: 20 mg progesterone cream (equivalent to 1/4 teaspoon Progest cream) is typically applied daily to rotating places on the body including upper arms, thighs, or breasts.
  • For breast pain associated with noncancerous breast disease: a typical dose of 4 grams of vaginal cream containing 2.5% natural progesterone is placed inside the vagina from the 19th to the 25th day of a 28-day cycle.
  • For restoring menstrual periods in women who have not reached menopause: one applicator (90 mg) of progesterone gel (Crinone 4% or 8%) is typically placed inside the vagina every other day for 6 days per month.
  • For hormone replacement therapy, one applicator (90 mg) of progesterone gel (Crinone 4% or 8%) is typically placed inside the vagina on days 17, 19, 21, 23, 25, and 27 of a 28-day cycle with 0.625 mg conjugated equine estrogens.
  • For reducing vaginal bleeding and reversing the thickening of the lining of the uterus in premenopausal women with noncancerous endometrial hyperplasia: a dose of 100 mg progesterone cream placed inside the vagina daily from day 10 to day 25 of a 28-day cycle has been used.


Abate, A., Perino, M., Abate, F. G., Brigandi, A., Costabile, L., and Manti, F. Intramuscular versus vaginal administration of progesterone for luteal phase support after in vitro fertilization and embryo transfer. A comparative randomized study. Clin.Exp.Obstet.Gynecol. 1999;26(3-4):203-206. View abstract.

Abiola, O. O., Checkley, S. A., Campbell, I. C., and Whatley, S. A. Effects of sex steroids on protein synthesis in cultured human lymphocytes. J.Psychiatr.Res. 1996;30(3):229-238. View abstract.

Abou-Saleh, M. T., Ghubash, R., Karim, L., Krymski, M., and Bhai, I. Hormonal aspects of postpartum depression. Psychoneuroendocrinology 1998;23(5):465-475. View abstract.

Al, Kadri H., Hassan, S., Al-Fozan, H. M., and Hajeer, A. Hormone therapy for endometriosis and surgical menopause. Cochrane.Database.Syst.Rev. 2009;(1):CD005997. View abstract.

Allen, W. M. Physiology of the corpus luteum, V: the preparation and some chemical properties of progestin, a hormone of the corpus luteum which produces progestational proliferation. 1930;

Aloia, J. F., Vaswani, A., Yeh, J. K., Ross, P. L., Flaster, E., and Dilmanian, F. A. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann.Intern.Med. 1-15-1994;120(2):97-103. View abstract.

Andersch, B. and Hahn, L. Progesterone treatment of premenstrual tension--a double blind study. J.Psychosom.Res. 1985;29(5):489-493. View abstract.

Andersen, M. L. and Tufik, S. Does male sexual behavior require progesterone? Brain Res.Rev. 2006;51(1):136-143. View abstract.

Andreen, L., Sundstrom-Poromaa, I., Bixo, M., Andersson, A., Nyberg, S., and Backstrom, T. Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone. Psychoneuroendocrinology 2005;30(2):212-224. View abstract.

Artini, P. G., Volpe, A., Angioni, S., Galassi, M. C., Battaglia, C., and Genazzani, A. R. A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program. J.Endocrinol.Invest 1995;18(1):51-56. View abstract.

Auger, C. J., Jessen, H. M., and Auger, A. P. Microarray profiling of gene expression patterns in adult male rat brain following acute progesterone treatment. Brain Res 1-5-2006;1067(1):58-66. View abstract.

Backstrom, T. and Mattsson, B. Correlation of symptoms in pre-menstrual tension to oestrogen and progesterone concentrations in blood plasma. A preliminary study. Neuropsychobiology 1975;1(2):80-86. View abstract.

Bayer, U. and Erdmann, G. The influence of sex hormones on functional cerebral asymmetries in postmenopausal women. Brain Cogn 2008;67(2):140-149. View abstract.

Becker, D., Creutzfeldt, O. D., Schwibbe, M., and Wuttke, W. Electrophysiological and psychological changes induced by steroid hormones in men and women. Acta Psychiatr.Belg. 1980;80(5):674-697. View abstract.

Beckers, N. G., Laven, J. S., Eijkemans, M. J., and Fauser, B. C. Follicular and luteal phase characteristics following early cessation of gonadotrophin-releasing hormone agonist during ovarian stimulation for in-vitro fertilization. Hum.Reprod. 2000;15(1):43-49. View abstract.

Belaisch-Allart J, de Mouzon J. Effect of luteal phase supplementation in an IVF programme after ovarian stimulation by LH-RH analogs:multicentric analysis [Effet de la supplémentation de la phase lutéale dans un programme de fécondation in vitro après stimulation de l'ovulation par les agonistes du LHRH. Journées de périconceptologie 1988;vol. 16, no7-8: pp. 654-656 (9 ref.).

Belaisch-Allart, J., Testart, J., Fries, N., Forman, R. G., and Frydman, R. The effect of dydrogesterone supplementation in an IVF programme. Hum.Reprod. 1987;2(3):183-185. View abstract.

Berle P, Budenz M Michaelis J.

Bicakci S, Uysal H Sarica Y Giray S Demirkiran M Bicakci K. Ischemic infarct - due to basilary migraine? The Pain Clinic. 2005;17(4):415-418.

Bloch, M., Schmidt, P. J., Danaceau, M., Murphy, J., Nieman, L., and Rubinow, D. R. Effects of gonadal steroids in women with a history of postpartum depression. Am.J.Psychiatry 2000;157(6):924-930. View abstract.

Bonduelle, M., Walker, J. J., and Calder, A. A. A comparative study of danazol and norethisterone in dysfunctional uterine bleeding presenting as menorrhagia. Postgrad.Med.J. 1991;67(791):833-836. View abstract.

Borna, S. and Sahabi, N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust.N.Z.J.Obstet.Gynaecol. 2008;48(1):58-63. View abstract.

Brambilla, F., Biggio, G., Pisu, M. G., Bellodi, L., Perna, G., Bogdanovich-Djukic, V., Purdy, R. H., and Serra, M. Neurosteroid secretion in panic disorder. Psychiatry Res. 5-30-2003;118(2):107-116. View abstract.

Bronson, Phyllis J. Mood biochemistry of women at mid-life.. Journal of Orthomolecular Medicine 2001;Vol 16(3):pp. 141-154.

Buyru F, Yalcin O Kovanci E Turfanda A. Danazol therapy in dysfunctional uterine bleeding [Turkish]. Istanbul Tip Fakultesi Mecmuasi 1995;

Calhoun, Karen S. and Burnette, M. Michele. Etiology and treatment of menstrual disorders. Behavioral Medicine Update, 1984;Vol 5(4),pp. 21-26.

Cameron, I. T., Haining, R., Lumsden, M. A., Thomas, V. R., and Smith, S. K. The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstet.Gynecol. 1990;76(1):85-88. View abstract.

Cameron, I. T., Leask, R., Kelly, R. W., and Baird, D. T. The effects of danazol, mefenamic acid, norethisterone and a progesterone-impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins 1987;34(1):99-110. View abstract.

Canuso, C. M., Goldstein, J. M., Wojcik, J., Dawson, R., Brandman, D., Klibanski, A., Schildkraut, J. J., and Green, A. I. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res. 8-5-2002;111(1):11-20. View abstract.

Chambers, K. C. Progesterone, estradiol, testosterone and dihydrotestosterone: effects on rate of extinction of a conditioned taste aversion in rats. Physiol Behav. 1980;24(6):1061-1065. View abstract.

Chouinard, G., Steinberg, S., and Steiner, W. Estrogen-progesterone combination: another mood stabilizer? Am.J.Psychiatry 1987;144(6):826. View abstract.

Chua, W. L., de Izquierdo, S. A., Kulkarni, J., and Mortimer, A. Estrogen for schizophrenia. Cochrane.Database.Syst.Rev. 2005;(4):CD004719. View abstract.

Claman, P., Domingo, M., and Leader, A. Luteal phase support in in-vitro fertilization using gonadotrophin releasing hormone analogue before ovarian stimulation: a prospective randomized study of human chorionic gonadotrophin versus intramuscular progesterone. Hum.Reprod. 1992;7(4):487-489. View abstract.

Clifford, K., Rai, R., Watson, H., Franks, S., and Regan, L. Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial. BMJ 6-15-1996;312(7045):1508-1511. View abstract.

Colucci, M., Cammarata, S., Assini, A., Croce, R., Clerici, F., Novello, C., Mazzella, L., Dagnino, N., Mariani, C., and Tanganelli, P. The number of pregnancies is a risk factor for Alzheimer's disease. Eur.J.Neurol. 2006;13(12):1374-1377. View abstract.

Colwell, K. A. and Tummon, I. S. Elevation of serum progesterone with oral micronized progesterone after in vitro fertilization. A randomized, controlled trial. J.Reprod.Med. 1991;36(3):170-172. View abstract.

Compton, R. J., Costello, C., and Diepold, J. Interhemispheric integration during the menstrual cycle: failure to confirm progesterone-mediated interhemispheric decoupling. Neuropsychologia 2004;42(11):1496-1503. View abstract.

Conway, C. A., Jones, B. C., DeBruine, L. M., Welling, L. L., Law Smith, M. J., Perrett, D. I., Sharp, M. A., and Al-Dujaili, E. A. Salience of emotional displays of danger and contagion in faces is enhanced when progesterone levels are raised. Horm.Behav. 2007;51(2):202-206. View abstract.

Corrado, F., Dugo, C., Cannata, M. L., Di, Bartolo M., Scilipoti, A., and Carlo, Stella N. A randomised trial of progesterone prophylaxis after midtrimester amniocentesis. Eur.J.Obstet.Gynecol.Reprod.Biol. 1-10-2002;100(2):196-198. View abstract.

Coutinho, E. M., De Souza, J. C., Barbosa, I. C., and Dourado, Silva, V. Long-lasting ovulation inhibition with a new injectable progestagen ORG-2154. Contraception 1982;25(6):551-560. View abstract.

Coutinho, Walmir, Appolinário, José C., Póvoa, Luiz C., and Meirelles, Ricardo. Terapia hormonal e os sintomas psíquicos na menopausa. Parte 2--Estudo duplo-cego dos efeitos da progesterona natural sobre os sintomas psíquicos da menopausa. = Hormonal therapy and the psychiatric symptoms in menopause: II. Double-blind study on the effects of natural progesterone on the affective symptoms in menopause.. Jornal Brasileiro de Psiquiatria 1995;Vol 44(5),pp. 223-229.

Crammer, J. L. Premenstrual depression, cortisol and oestradiol treatment. Psychol.Med. 1986;16(2):451-455. View abstract.

Cutler, S. M., VanLandingham, J. W., Murphy, A. Z., and Stein, D. G. Slow-release and injected progesterone treatments enhance acute recovery after traumatic brain injury. Pharmacol.Biochem.Behav. 2006;84(3):420-428. View abstract.

da Fonseca, E. B., Bittar, R. E., Carvalho, M. H., and Zugaib, M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am.J.Obstet.Gynecol. 2003;188(2):419-424. View abstract.

Daftary, G. S. and Taylor, H. S. Endocrine regulation of HOX genes. Endocr.Rev. 2006;27(4):331-355. View abstract.

Daitzman, Reid and Zuckerman, Marvin. Disinhibitory sensation seeking, personality and gonadal hormones. . Personality and Individual Differences, 1980;Vol 1(2):pp. 103-110.

Dalton, K. Ante-natal progesterone and intelligence. Br.J.Psychiatry 1968;114(516):1377-1382. View abstract.

Dalton, K. Controlled trials in the prophylactic value of progesterone in the treatment of pre-eclamptic toxaemia. J.Obstet.Gynaecol.Br.Emp. 1962;69:463-468. View abstract.

Dalton, K. Prenatal progesterone and educational attainments. Br.J.Psychiatry 1976;129:438-442. View abstract.

Daly, R. C., Schmidt, P. J., Davis, C. L., Danaceau, M. A., and Rubinow, D. R. Effects of gonadal steroids on peripheral benzodiazepine receptor density in women with PMS and controls. Psychoneuroendocrinology 2001;26(6):539-549. View abstract.

Daya, S. and Gunby, J. L. WITHDRAWN: Luteal phase support in assisted reproduction cycles. Cochrane.Database.Syst.Rev. 2008;(3):CD004830. View abstract.

de, Lignieres B., Dennerstein, L., and Backstrom, T. Influence of route of administration on progesterone metabolism. Maturitas 1995;21(3):251-257. View abstract.

de, Wit H., Schmitt, L., Purdy, R., and Hauger, R. Effects of acute progesterone administration in healthy postmenopausal women and normally-cycling women. Psychoneuroendocrinology 2001;26(7):697-710. View abstract.

Deligdisch, L. Effects of hormone therapy on the endometrium. Mod.Pathol. 1993;6(1):94-106. View abstract.

Denis, C., Fatseas, M., Lavie, E., and Auriacombe, M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane.Database.Syst.Rev. 2006;3:CD005194. View abstract.

Dennis, C. L. Preventing postpartum depression part I: a review of biological interventions. Can.J.Psychiatry 2004;49(7):467-475. View abstract.

Dennis, C. L., Ross, L. E., and Herxheimer, A. Oestrogens and progestins for preventing and treating postpartum depression. Cochrane.Database.Syst.Rev. 2008;(4):CD001690. View abstract.

Dodd, J. M., Flenady, V., Cincotta, R., and Crowther, C. A. Prenatal administration of progesterone for preventing preterm birth. Cochrane.Database.Syst.Rev. 2006;(1):CD004947. View abstract.

Drake, E. B., Henderson, V. W., Stanczyk, F. Z., McCleary, C. A., Brown, W. S., Smith, C. A., Rizzo, A. A., Murdock, G. A., and Buckwalter, J. G. Associations between circulating sex steroid hormones and cognition in normal elderly women. Neurology 2-8-2000;54(3):599-603. View abstract.

Edler, C., Lipson, S. F., and Keel, P. K. Ovarian hormones and binge eating in bulimia nervosa. Psychol.Med. 2007;37(1):131-141. View abstract.

El-Zibdeh, M. Y. Dydrogesterone in the reduction of recurrent spontaneous abortion. J.Steroid Biochem.Mol.Biol. 2005;97(5):431-434. View abstract.

Erdinçler, DS. Yasli Kadin ve Erkeklerde Depresi f Duygudurum ve Endojen Seks Hormonlari Arasindaki I li ki . = Relationships Between Depressive Mood and Endogenous Sex Hormone Levels in Elderly Women and Men. Yeni Symposium: psikiyatri, nöroloji ve davranis bilimleri dergisi. 2003;41(1):22-30.

Eriksson, E., Sundblad, C., Lisjo, P., Modigh, K., and Andersch, B. Serum levels of androgens are higher in women with premenstrual irritability and dysphoria than in controls. Psychoneuroendocrinology 1992;17(2-3):195-204. View abstract.

Facchinetti, F., Paganelli, S., Comitini, G., Dante, G., and Volpe, A. Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate. Am.J.Obstet.Gynecol. 2007;196(5):453-454. View abstract.

Feksi, A., Harris, B., Walker, R. F., Riad-Fahmy, D., and Newcombe, R. G. 'Maternity blues' and hormone levels in saliva. J.Affect.Disord. 1984;6(3-4):351-355. View abstract.

Fernandez, G., Weis, S., Stoffel-Wagner, B., Tendolkar, I., Reuber, M., Beyenburg, S., Klaver, P., Fell, J., de, Greiff A., Ruhlmann, J., Reul, J., and Elger, C. E. Menstrual cycle-dependent neural plasticity in the adult human brain is hormone, task, and region specific. J.Neurosci. 5-1-2003;23(9):3790-3795. View abstract.

Ferre, F., Uzan, M., Janssens, Y., Tanguy, G., Jolivet, A., Breuiller, M., Sureau, C., and Cedard, L. Oral administration of micronized natural progesterone in late human pregnancy. Effects on progesterone and estrogen concentrations in the plasma, placenta, and myometrium. Am.J.Obstet.Gynecol. 1-1-1984;148(1):26-34. View abstract.

Field, F. J., Kam, N. T., and Mathur, S. N. Regulation of cholesterol metabolism in the intestine. Gastroenterology 1990;99(2):539-551. View abstract.

Finn, D. A., Beadles-Bohling, A. S., Beckley, E. H., Ford, M. M., Gililland, K. R., Gorin-Meyer, R. E., and Wiren, K. M. A new look at the 5alpha-reductase inhibitor finasteride. CNS.Drug Rev. 2006;12(1):53-76. View abstract.

Fonseca, E. B., Celik, E., Parra, M., Singh, M., and Nicolaides, K. H. Progesterone and the risk of preterm birth among women with a short cervix. N.Engl.J.Med. 8-2-2007;357(5):462-469. View abstract.

Ford, O., Lethaby, A., Roberts, H., and Mol, B. W. Progesterone for premenstrual syndrome. Cochrane.Database.Syst.Rev 2009;(2):CD003415. View abstract.

Fraser, I. S. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust.N.Z.J.Obstet.Gynaecol. 1990;30(4):353-356. View abstract.

Freeman, E. W., Rickels, K., and Sondheimer, S. J. Course of premenstrual syndrome symptom severity after treatment. Am.J.Psychiatry 1992;149(4):531-533. View abstract.

Funderburk, S. J., Carter, J., Tanguay, P., Freeman, B. J., and Westlake, J. R. Parental reproductive problems and gestational hormonal exposure in autistic and schizophrenic children. J.Autism Dev.Disord. 1983;13(3):325-332. View abstract.

Gerhard, I., Gwinner, B., Eggert-Kruse, W., and Runnebaum, B. Double-blind controlled trial of progesterone substitution in threatened abortion. Biol.Res.Pregnancy.Perinatol. 1987;8(1 1ST Half):26-34. View abstract.

Geusa S, Causio F Marinaccio M Stanziano A Sarcina E. Luteal phase support with progesterone in IVF/ET cycles: a prospective, randomized study comparing vaginal and intramuscular administration [abstract]. Human Reproduction 2001;

Girdler, S. S., O'Briant, C., Steege, J., Grewen, K., and Light, K. C. A comparison of the effect of estrogen with or without progesterone on mood and physical symptoms in postmenopausal women. J.Womens Health Gend.Based.Med. 1999;8(5):637-646. View abstract.

Golan, A., Herman, A., Soffer, Y., Bukovsky, I., Caspi, E., and Ron-El, R. Human chorionic gonadotrophin is a better luteal support than progesterone in ultrashort gonadotrophin-releasing hormone agonist/menotrophin in-vitro fertilization cycles. Hum.Reprod. 1993;8(9):1372-1375. View abstract.


Gregoire, A. J., Kumar, R., Everitt, B., Henderson, A. F., and Studd, J. W. Transdermal oestrogen for treatment of severe postnatal depression. Lancet 4-6-1996;347(9006):930-933. View abstract.

Gron, G., Friess, E., Herpers, M., and Rupprecht, R. Assessment of cognitive performance after progesterone administration in healthy male volunteers. Neuropsychobiology 1997;35(3):147-151. View abstract.

Groswasser, Z., Cohen, M., and Keren, O. Female TBI patients recover better than males. Brain Inj. 1998;12(9):805-808. View abstract.

Gruber, C. J. and Huber, J. C. Differential effects of progestins on the brain. Maturitas 12-10-2003;46 Suppl 1:S71-S75. View abstract.

Haas, D. M. and Ramsey, P. S. Progestogen for preventing miscarriage. Cochrane.Database.Syst.Rev. 2008;(2):CD003511. View abstract.

Haimov-Kochman, R. and Hochner-Celnikier, D. Hot flashes revisited: pharmacological and herbal options for hot flashes management. What does the evidence tell us? Acta Obstet Gynecol.Scand 2005;84(10):972-979. View abstract.

Halbreich, U., Endicott, J., Goldstein, S., and Nee, J. Premenstrual changes and changes in gonadal hormones. Acta Psychiatr.Scand. 1986;74(6):576-586. View abstract.

Hardoy, M. C., Serra, M., Carta, M. G., Contu, P., Pisu, M. G., and Biggio, G. Increased neuroactive steroid concentrations in women with bipolar disorder or major depressive disorder. J.Clin.Psychopharmacol. 2006;26(4):379-384. View abstract.

Harris, B., Johns, S., Fung, H., Thomas, R., Walker, R., Read, G., and Riad-Fahmy, D. The hormonal environment of post-natal depression. Br.J.Psychiatry 1989;154:660-667. View abstract.

Harris, B., Lovett, L., Smith, J., Read, G., Walker, R., and Newcombe, R. Cardiff puerperal mood and hormone study. III. Postnatal depression at 5 to 6 weeks postpartum, and its hormonal correlates across the peripartum period. Br.J.Psychiatry 1996;168(6):739-744. View abstract.

Hartikainen-Sorri, A. L., Kauppila, A., and Tuimala, R. Inefficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstet.Gynecol. 1980;56(6):692-695. View abstract.

Hastrup, J. L. and Light, K. C. Sex differences in cardiovascular stress responses: modulation as a function of menstrual cycle phases. J.Psychosom.Res. 1984;28(6):475-483. View abstract.

Hausmann, M. and Gunturkun, O. Steroid fluctuations modify functional cerebral asymmetries: the hypothesis of progesterone-mediated interhemispheric decoupling. Neuropsychologia 2000;38(10):1362-1374. View abstract.

Hausmann, Markus and Güntürkün, Onur. Der Einfluss von Sexualhormonen auf funktionelle cerebrale Asymmetrien. = Influence of sex hormones on functional cerebral asymmetry. Zeitschrift für Neuropsychologie, 2002;Vol 11(4):pp. 203-215.

Hauth, J. C., Gilstrap, L. C., III, Brekken, A. L., and Hauth, J. M. The effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population. Am.J.Obstet.Gynecol. 5-15-1983;146(2):187-190. View abstract.

Heidrich, A., Schleyer, M., Spingler, H., Albert, P., Knoche, M., Fritze, J., and Lanczik, M. Postpartum blues: relationship between not-protein bound steroid hormones in plasma and postpartum mood changes. J.Affect.Disord. 1994;30(2):93-98. View abstract.

Heinrich, A. B. and Wolf, O. T. Investigating the effects of estradiol or estradiol/progesterone treatment on mood, depressive symptoms, menopausal symptoms and subjective sleep quality in older healthy hysterectomized women: a questionnaire study. Neuropsychobiology 2005;52(1):17-23. View abstract.

HEUSER, G., KALES, A., and JACOBSON, A. Human sleep patterns after progesterone administration. Psychophysiology 1968; 4(3):pp. 378.

Hibbeln, J. R., Palmer, J. W., and Davis, J. M. Are disturbances in lipid-protein interactions by phospholipase-A2 a predisposing factor in affective illness? Biol.Psychiatry 4-1-1989;25(7):945-961. View abstract.

Hickey, M., Higham, J., and Fraser, I. S. Progestogens versus oestrogens and progestogens for irregular uterine bleeding associated with anovulation. Cochrane.Database.Syst.Rev. 2007;(4):CD001895. View abstract.

Hingham, J. M. and Shaw, R. W. A comparative study of danazol, a regimen of decreasing doses of danazol, and norethindrone in the treatment of objectively proven unexplained menorrhagia. Am.J.Obstet.Gynecol. 1993;169(5):1134-1139. View abstract.

Hogervorst, E., Yaffe, K., Richards, M., and Huppert, F. A. Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane.Database.Syst.Rev. 2009;(1):CD003799. View abstract.

Hsiao, C. C., Liu, C. Y., and Hsiao, M. C. No correlation of depression and anxiety to plasma estrogen and progesterone levels in patients with premenstrual dysphoric disorder. Psychiatry Clin.Neurosci. 2004;58(6):593-599. View abstract.

Hunt, R., Davis, P. G., and Inder, T. Replacement of estrogens and progestins to prevent morbidity and mortality in preterm infants. Cochrane.Database.Syst.Rev. 2004;(4):CD003848. View abstract.

Hutt, S. J., Frank, G., Mychalkiw, W., and Hughes, M. Perceptual--motor performance during the menstrual cycle. Horm.Behav. 1980;14(2):116-125. View abstract.

Ingram JC, Greenwood RJ Woolridge MW. Hormonal predictors of postnatal depression at 6 months in breastfeeding women. . Journal of Reproductive and Infant Psychology. 2003;21(1):61-68.

Irvine, G. A., Campbell-Brown, M. B., Lumsden, M. A., Heikkila, A., Walker, J. J., and Cameron, I. T. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br.J.Obstet.Gynaecol. 1998;105(6):592-598. View abstract.

Jacklin, C. N., Maccoby, E. E., and Doering, C. H. Neonatal sex-steroid hormones and timidity in 6-18-month-old boys and girls. Dev.Psychobiol. 1983;16(3):163-168. View abstract.

Johnson, J. W., Austin, K. L., Jones, G. S., Davis, G. H., and King, T. M. Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. N.Engl.J.Med. 10-2-1975;293(14):675-680. View abstract.

Johnston, V. S. and Wang, X. T. The relationship between menstrual phase and the P3 component of ERPs. Psychophysiology 1991;28(4):400-409. View abstract.

Kauppila, A., Telimaa, S., Ronnberg, L., and Vuori, J. Placebo-controlled study on serum concentrations of CA-125 before and after treatment of endometriosis with danazol or high-dose medroxyprogesterone acetate alone or after surgery. Fertil.Steril. 1988;49(1):37-41. View abstract.

Khalil, R. A. Sex hormones as potential modulators of vascular function in hypertension. Hypertension 2005;46(2):249-254. View abstract.

Kivlighan, K. T., Granger, D. A., and Schwartz, E. B. Blood contamination and the measurement of salivary progesterone and estradiol. Horm.Behav. 2005;47(3):367-370. View abstract.

Klatzkin, R. R., Morrow, A. L., Light, K. C., Pedersen, C. A., and Girdler, S. S. Associations of histories of depression and PMDD diagnosis with allopregnanolone concentrations following the oral administration of micronized progesterone. Psychoneuroendocrinology 2006;31(10):1208-1219. View abstract.

KlopperA, MacNaughtonM. Hormones in recurrent abortion.. Jour-nal of Obstetrics and Gynaecology of the British Commonwealth 1965;

Kukuvitis, A., Kourtis, A., Papaiconomou, N., Zournatzi, V., Makedos, G., and Panidis, D. Differential effects of unopposed versus opposed hormone therapy, tibolone, and raloxifene on substance p levels. Fertil.Steril. 2003;80(1):96-98. View abstract.

Kupferminc, M. J., Lessing, J. B., Amit, A., Yovel, I., David, M. P., and Peyser, M. R. A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in-vitro fertilization and embryo transfer. Hum.Reprod. 1990;5(3):271-273. View abstract.

Kushner, S. A. and Guze, B. H. Treatment of psychomotor agitation and self-injurious behavior with estrogen and progesterone in a patient with Sanfilippo syndrome. Gen.Hosp.Psychiatry 2005;27(4):298-300. View abstract.

LANDAU, R. L., BERGENSTAL, D. M., LUGIBIHL, K., and KASCHT, M. E. The metabolic effects of progesterone in man. J.Clin.Endocrinol.Metab 1955;15(10):1194-1215. View abstract.

Lawrie, T. A., Hofmeyr, G. J., De, Jager M., Berk, M., Paiker, J., and Viljoen, E. A double-blind randomised placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. Br.J.Obstet.Gynaecol. 1998;105(10):1082-1090. View abstract.

Le Vine L. Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery 1964;;

Leonetti, H. B., Landes, J., Steinberg, D., and Anasti, J. N. Transdermal progesterone cream as an alternative progestin in hormone therapy. Altern.Ther.Health Med. 2005;11(6):36-38. View abstract.

Lethaby, A. E., Cooke, I., and Rees, M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane.Database.Syst.Rev. 2005;(4):CD002126. View abstract.

Lethaby, A. E., Cooke, I., and Rees, M. Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding. Cochrane.Database.Syst.Rev. 2000;(2):CD002126. View abstract.

Lethaby, A., Irvine, G., and Cameron, I. Cyclical progestogens for heavy menstrual bleeding. Cochrane.Database.Syst.Rev. 2000;(2):CD001016. View abstract.

Lethaby, A., Irvine, G., and Cameron, I. Cyclical progestogens for heavy menstrual bleeding. Cochrane.Database.Syst.Rev. 2008;(1):CD001016. View abstract.

Little, B. C., Matta, R. J., and Zahn, T. P. Physiological and psychological effects of progesterone in man. J.Nerv.Ment.Dis. 1974;159(4):256-262. View abstract.

Loh SKE, Leong NKY. Luteal phase support in IVF cycles - is intramuscular progesterone the therapy of choice? [abstract]. FertilitySociety of Australia XV Annual Meeting Abstract Book. 1996;Abs #O24.

Low, L. F., Anstey, K. J., Jorm, A. F., Christensen, H., and Rodgers, B. Hormone replacement therapy and cognition in an Australian representative sample aged 60-64 years. Maturitas 4-20-2006;54(1):86-94. View abstract.

Lu, N. Z. and Bethea, C. L. Ovarian steroid regulation of 5-HT1A receptor binding and G protein activation in female monkeys. Neuropsychopharmacology 2002;27(1):12-24. View abstract.

Luconi, M., Bonaccorsi, L., Maggi, M., Pecchioli, P., Krausz, C., Forti, G., and Baldi, E. Identification and characterization of functional nongenomic progesterone receptors on human sperm membrane. J.Clin.Endocrinol.Metab 1998;83(3):877-885. View abstract.

Ludwig, M., Finas, A., Katalinic, A., Strik, D., Kowalcek, I., Schwartz, P., Felberbaum, R., Kupker, W., Schopper, B., Al-Hasani, S., and Diedrich, K. Prospective, randomized study to evaluate the success rates using hCG, vaginal progesterone or a combination of both for luteal phase support. Acta Obstet.Gynecol.Scand. 2001;80(6):574-582. View abstract.

Lydeking-Olsen, E., Beck-Jensen, J. E., Setchell, K. D., and Holm-Jensen, T. Soymilk or progesterone for prevention of bone loss--a 2 year randomized, placebo-controlled trial. Eur.J Nutr. 2004;43(4):246-257. View abstract.

Magill, P. J. Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. progesterone Study Group. Br.J.Gen.Pract. 1995;45(400):589-593. View abstract.

Maki, P. M., Rich, J. B., and Rosenbaum, R. S. Implicit memory varies across the menstrual cycle: estrogen effects in young women. Neuropsychologia 2002;40(5):518-529. View abstract.

Manber, R., Kuo, T. F., Cataldo, N., and Colrain, I. M. The effects of hormone replacement therapy on sleep-disordered breathing in postmenopausal women: a pilot study. Sleep 3-15-2003;26(2):163-168. View abstract.

Martin, C. A., Mainous, A. G., III, Mainous, R. O., Oler, M. J., Curry, T., and Vore, M. Progesterone and adolescent suicidality. Biol.Psychiatry 11-15-1997;42(10):956-958. View abstract.

Martinez, F., Coroleu, B., Parera, N., Alvarez, M., Traver, J. M., Boada, M., and Barri, P. N. Human chorionic gonadotropin and intravaginal natural progesterone are equally effective for luteal phase support in IVF. Gynecol.Endocrinol. 2000;14(5):316-320. View abstract.

Martorano, J. Case study: The use of the CEEG in treating premenstrual syndrome: An opportunity for treatment innovation. . Integrative Psychiatry, 1991;Vol 7(1), pp. 63-64.

Meakin, C. and Brockington, I. F. Failure of progesterone treatment in puerperal mania. Br.J.Psychiatry 1990;156:910. View abstract.

Meher, S. and Duley, L. Progesterone for preventing pre-eclampsia and its complications. Cochrane.Database.Syst.Rev. 2006;(4):CD006175. View abstract.

Meis, P. J., Klebanoff, M., Thom, E., Dombrowski, M. P., Sibai, B., Moawad, A. H., Spong, C. Y., Hauth, J. C., Miodovnik, M., Varner, M. W., Leveno, K. J., Caritis, S. N., Iams, J. D., Wapner, R. J., Conway, D., O'Sullivan, M. J., Carpenter, M., Mercer, B., Ramin, S. M., Thorp, J. M., Peaceman, A. M., and Gabbe, S. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N.Engl.J.Med. 6-12-2003;348(24):2379-2385. View abstract.

Michener, W., Rozin, P., Freeman, E., and Gale, L. The role of low progesterone and tension as triggers of perimenstrual chocolate and sweets craving: some negative experimental evidence. Physiol Behav. 1999;67(3):417-420. View abstract.

Mizuki, Yasushi, Kajimura, Naofumi, Miyoshi, Akira, and Ushijima, Itsuko. Neuroendocrinological studies on patients with periodic psychosis of adolescence before and after menarche. Integrative Psychiatry 1991;Vol 7(3-4): pp. 241-247.

Moller K, Fuchs F. Double blind controlled trial of 6-methyl-17-acetoxyprogesterone in threatened abortion. Journal of Obstetrics andGynaecology of the British Commonwealth 1965;72:1042-4.

Moses, E. L., Drevets, W. C., Smith, G., Mathis, C. A., Kalro, B. N., Butters, M. A., Leondires, M. P., Greer, P. J., Lopresti, B., Loucks, T. L., and Berga, S. L. Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. Biol.Psychiatry 10-15-2000;48(8):854-860. View abstract.

Moses-Kolko, E. L., Meltzer, C. C., Greer, P., Butters, M., Berga, S. L., Smith, G., and Drevets, W. C. Estradiol effects on the postmenopausal brain. Am.J.Psychiatry 2004;161(11):2136. View abstract.

Murphy, B. E., Abbott, F. V., Allison, C. M., Watts, C., and Ghadirian, A. M. Elevated levels of some neuroactive progesterone metabolites, particularly isopregnanolone, in women with chronic fatigue syndrome. Psychoneuroendocrinology 2004;29(2):245-268. View abstract.

Murray, D. Recurrence of puerperal psychosis not prevented by prophylactic progesterone administration. J.Nerv.Ment.Dis. 1990;178(8):537-538. View abstract.

Nicoletti, A., Arabia, G., Pugliese, P., Nicoletti, G., Torchia, G., Condino, F., Morgante, L., Quattrone, A., and Zappia, M. Hormonal replacement therapy in women with Parkinson disease and levodopa-induced dyskinesia: a crossover trial. Clin.Neuropharmacol. 2007;30(5):276-280. View abstract.

Nyboe, Andersen A., Popovic-Todorovic, B., Schmidt, K. T., Loft, A., Lindhard, A., Hojgaard, A., Ziebe, S., Hald, F., Hauge, B., and Toft, B. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Hum.Reprod. 2002;17(2):357-361. View abstract.

O'Brien, J. M., Adair, C. D., Lewis, D. F., Hall, D. R., Defranco, E. A., Fusey, S., Soma-Pillay, P., Porter, K., How, H., Schackis, R., Eller, D., Trivedi, Y., Vanburen, G., Khandelwal, M., Trofatter, K., Vidyadhari, D., Vijayaraghavan, J., Weeks, J., Dattel, B., Newton, E., Chazotte, C., Valenzuela, G., Calda, P., Bsharat, M., and Creasy, G. W. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet.Gynecol. 2007;30(5):687-696. View abstract.

Ordyan, N. E. and Pivina, S. G. Anxiety levels and neurosteroid synthesis in the brains of prenatally stressed male rats. Neurosci.Behav.Physiol 2003;33(9):899-903. View abstract.

Oshima, M., Inagi, T., Yokoyama, K., Kikutani, T., Sugimoto, K., Shimada, Y., Ogawa, R., and Menkes, D. L. Pregnancy-related increases in sensory perception thresholds are not correlated with serum progesterone levels. Pain Pract. 2003;3(2):120-124. View abstract.

Overton, C. E., Lindsay, P. C., Johal, B., Collins, S. A., Siddle, N. C., Shaw, R. W., and Barlow, D. H. A randomized, double-blind, placebo-controlled study of luteal phase dydrogesterone (Duphaston) in women with minimal to mild endometriosis. Fertil.Steril. 1994;62(4):701-707. View abstract.

Paetz D, Kruskemper G Gillich KH. Psychological test performance in hospitalized climacteric patients during treatment of internal disorders, with special emphasis on the effects of estrogens and progesterone. . Zeitschrift für Gerontologie. 1975;8(5):358-364.

Paganini-Hill, A. and Henderson, V. W. The effects of hormone replacement therapy, lipoprotein cholesterol levels, and other factors on a clock drawing task in older women. J.Am.Geriatr.Soc. 1996;44(7):818-822. View abstract.

Palagiano, A., Bulletti, C., Pace, M. C., DE, Ziegler D., Cicinelli, E., and Izzo, A. Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy. Ann.N.Y.Acad.Sci. 2004;1034:200-210. View abstract.

Papiernik-Berkhauer E. Double blind study of an agent to prevent preterm delivery among women at increased risk [Etude en double aveugle d'un medicament prevenant la survenue prematuree de l'accouchement chez les femmes a risque eleve d'accouchement premature]. Edition Schering Serie IV 1970;Vol. 3:65-8.

Park, M. K., Kwon, H. Y., Ahn, W. S., Bae, S., Rhyu, M. R., and Lee, Y. Estrogen activities and the cellular effects of natural progesterone from wild yam extract in mcf-7 human breast cancer cells. Am.J.Chin Med. 2009;37(1):159-167. View abstract.

Phillips, S. M. and Sherwin, B. B. Variations in memory function and sex steroid hormones across the menstrual cycle. Psychoneuroendocrinology 1992;17(5):497-506. View abstract.

Pisanty, S., Rafaely, B., and Polishuk, W. The effect of steroid hormones on buccal mucosa of menopausal women. Oral Surg.Oral Med.Oral Pathol. 1975;40(3):346-353. View abstract.

Porcu E. Intramuscular versus vaginal progesterone in assisted reproduction [abstract]. Fertility and Sterility 2003;Vol. 80(issue suppl3:S131 (Abs # P-32).)

Prentice, A., Deary, A. J., and Bland, E. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane.Database.Syst.Rev. 2000;(2):CD002122. View abstract.

Preston, J. T., Cameron, I. T., Adams, E. J., and Smith, S. K. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br.J.Obstet.Gynaecol. 1995;102(5):401-406. View abstract.

Propst, A. M., Hill, J. A., Ginsburg, E. S., Hurwitz, S., Politch, J., and Yanushpolsky, E. H. A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization-embryo transfer cycles. Fertil.Steril. 2001;76(6):1144-1149. View abstract.

Rasmusson, A. M., Vasek, J., Lipschitz, D. S., Vojvoda, D., Mustone, M. E., Shi, Q., Gudmundsen, G., Morgan, C. A., Wolfe, J., and Charney, D. S. An increased capacity for adrenal DHEA release is associated with decreased avoidance and negative mood symptoms in women with PTSD. Neuropsychopharmacology 2004;29(8):1546-1557. View abstract.

Recker, R. R., Davies, K. M., Dowd, R. M., and Heaney, R. P. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. Ann.Intern.Med. 6-1-1999;130(11):897-904. View abstract.

Redei, E. and Freeman, E. W. Daily plasma estradiol and progesterone levels over the menstrual cycle and their relation to premenstrual symptoms. Psychoneuroendocrinology 1995;20(3):259-267. View abstract.

Reijnders, F. J., Thomas, C. M., Doesburg, W. H., Rolland, R., and Eskes, T. K. Endocrine effects of 17 alpha-hydroxyprogesterone caproate during early pregnancy: a double-blind clinical trial. Br.J.Obstet.Gynaecol. 1988;95(5):462-468. View abstract.

Rettenbacher, M. A., Mechtcheriakov, S., Bergant, A., Brugger, A., and Fleischhacker, W. W. Improvement of psychosis during treatment with estrogen and progesterone in a patient with hypoestrogenemia. J.Clin.Psychiatry 2004;65(2):275-277. View abstract.

Richter MA, Haltvick R Shapiro SS. Progesterone treatment of premenstrual syndrome. Current Therapeutic Research. 1984;36(5, Sect 2):840-850.

Rigaud, A. S., Andre, G., Vellas, B., Touchon, J., and Pere, J. J. No additional benefit of HRT on response to rivastigmine in menopausal women with AD. Neurology 1-14-2003;60(1):148-149. View abstract.

Riis, B., Thomsen, K., and Christiansen, C. Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. N.Engl.J Med. 1-22-1987;316(4):173-177. View abstract.

Ritsner, M., Gibel, A., Ram, E., Maayan, R., and Weizman, A. Alterations in DHEA metabolism in schizophrenia: two-month case-control study. Eur.Neuropsychopharmacol. 2006;16(2):137-146. View abstract.

Roglio, I., Giatti, S., Pesaresi, M., Bianchi, R., Cavaletti, G., Lauria, G., Garcia-Segura, L. M., and Melcangi, R. C. Neuroactive steroids and peripheral neuropathy. Brain Res.Rev. 2008;57(2):460-469. View abstract.

Rosenberg, E. J. The relationship between hormonal changes and psychophysiological measures in women. Biol.Psychol.Bull. 1980;6(1):46-56. View abstract.

Rosenberg, S. M., Luciano, A. A., and Riddick, D. H. The luteal phase defect: the relative frequency of, and encouraging response to, treatment with vaginal progesterone. Fertil.Steril. 1980;34(1):17-20. View abstract.

Rouse, D. J., Caritis, S. N., Peaceman, A. M., Sciscione, A., Thom, E. A., Spong, C. Y., Varner, M., Malone, F., Iams, J. D., Mercer, B. M., Thorp, J., Sorokin, Y., Carpenter, M., Lo, J., Ramin, S., Harper, M., and Anderson, G. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N.Engl.J.Med. 8-2-2007;357(5):454-461. View abstract.

Rupprecht, R., Reul, J. M., van, Steensel B., Spengler, D., Soder, M., Berning, B., Holsboer, F., and Damm, K. Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur.J.Pharmacol. 10-15-1993;247(2):145-154. View abstract.

Ryan, N. and Rosner, A. Quality of life and costs associated with micronized progesterone and medroxyprogesterone acetate in hormone replacement therapy for nonhysterectomized, postmenopausal women. Clin.Ther. 2001;23(7):1099-1115. View abstract.

Saarikoski, S., Yliskoski, M., and Penttila, I. Sequential use of norethisterone and natural progesterone in pre-menopausal bleeding disorders. Maturitas 1990;12(2):89-97. View abstract.

Sampson, G. A. Premenstrual syndrome: a double-blind controlled trial of progesterone and placebo. Br.J.Psychiatry 1979;135:209-215. View abstract.

Sandyk, R. Estrogen's impact on cognitive functions in multiple sclerosis. Int.J.Neurosci. 1996;86(1-2):23-31. View abstract.

Saucedo LLE, Galache VP Hernandez AS Santos HR Arenas ML Patrizio P. Randomized trial of three different forms of progesterone supplementation in ART: preliminary results [abstract]. Fertility and Sterility 2000;74((Suppl 1):S150 (Abs # P-175).)

Saucedo-de la Llata E, Batiza V Arenas L Santos R Galache P Hernandez-Ayup S et al. Progesterone for luteal support: randomized, prospective trial comparing vaginal and i.m. administration [abstract]. Human Reproduction 2003;

Schaller, J. L., Briggs, B., and Briggs, M. Progesterone organogel for premenstrual dysphoric disorder. J.Am.Acad.Child Adolesc.Psychiatry 2000;39(5):546-547. View abstract.

Schilling, C., Gallicchio, L., Miller, S. R., Langenberg, P., Zacur, H., and Flaws, J. A. Genetic polymorphisms, hormone levels, and hot flashes in midlife women. Maturitas 6-20-2007;57(2):120-131. View abstract.

Schouenborg, L. O., Honnens de, Lichtenberg M., Djursing, H., and Sorensen, J. [Hyperemesis gravidarum]. Ugeskr.Laeger 4-6-1992;154(15):1015-1019. View abstract.

Schultheiss, O. C., Wirth, M. M., and Stanton, S. J. Effects of affiliation and power motivation arousal on salivary progesterone and testosterone. Horm.Behav. 2004;46(5):592-599. View abstract.

Schussler, P., Kluge, M., Yassouridis, A., Dresler, M., Held, K., Zihl, J., and Steiger, A. Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women. Psychoneuroendocrinology 2008;33(8):1124-1131. View abstract.

Shantha, S., Brooks-Gunn, J., Locke, R. J., and Warren, M. P. Natural vaginal progesterone is associated with minimal psychological side effects: a preliminary study. J.Womens Health Gend.Based.Med. 2001;10(10):991-997. View abstract.

SHEARMAN, R. P. and GARRETT, W. J. Double-blind study of effect of 17-hydroxyprogesterone caproate on abortion rate. Br.Med.J. 2-2-1963;1(5326):292-295. View abstract.

Shippen, E. R. and West, W. J., Jr. Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil.Steril. 2004;81(5):1395-1398. View abstract.

Shirtcliff, E. A., Reavis, R., Overman, W. H., and Granger, D. A. Measurement of gonadal hormones in dried blood spots versus serum: verification of menstrual cycle phase. Horm.Behav. 2001;39(4):258-266. View abstract.

Shu, J., Miao, P., and Wang, R. J. [Clinical observation on effect of Chinese herbal medicine plus human chorionic gonadotropin and progesterone in treating anticardiolipin antibody-positive early recurrent spontaneous abortion]. Zhongguo Zhong.Xi.Yi.Jie.He.Za Zhi. 2002;22(6):414-416. View abstract.

Shumin, X., Johannisson, E., Landgren, B. M., and Diczfalusy, E. Pituitary, ovarian and endometrial effects of progesterone released prematurely during the proliferative phase. Contraception 1983;27(2):177-193. View abstract.

Sita, A. and Miller, S. B. Estradiol, progesterone and cardiovascular response to stress. Psychoneuroendocrinology 1996;21(3):339-346. View abstract.

Sitruk-Ware, R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging 2004;21(13):865-883. View abstract.

Smith, M. J., Adams, L. F., Schmidt, P. J., Rubinow, D. R., and Wassermann, E. M. Abnormal luteal phase excitability of the motor cortex in women with premenstrual syndrome. Biol.Psychiatry 10-1-2003;54(7):757-762. View abstract.

Soderpalm, A. H., Lindsey, S., Purdy, R. H., Hauger, R., and Wit, de H. Administration of progesterone produces mild sedative-like effects in men and women. Psychoneuroendocrinology 2004;29(3):339-354. View abstract.

Sofuoglu, M., Mitchell, E., and Kosten, T. R. Effects of progesterone treatment on cocaine responses in male and female cocaine users. Pharmacol.Biochem.Behav. 2004;78(4):699-705. View abstract.

Sofuoglu, M., Poling, J., Gonzalez, G., Gonsai, K., Oliveto, A., and Kosten, T. R. Progesterone effects on cocaine use in male cocaine users maintained on methadone: a randomized, double-blind, pilot study. Exp.Clin.Psychopharmacol. 2007;15(5):453-460. View abstract.

Solis-Ortiz, S. and Corsi-Cabrera, M. Sustained attention is favored by progesterone during early luteal phase and visuo-spatial memory by estrogens during ovulatory phase in young women. Psychoneuroendocrinology 2008;33(7):989-998. View abstract.

Solis-Ortiz, S., Guevara, M. A., and Corsi-Cabrera, M. Performance in a test demanding prefrontal functions is favored by early luteal phase progesterone: an electroencephalographic study. Psychoneuroendocrinology 2004;29(8):1047-1057. View abstract.

Song, Y. L. and Zhu, L. P. [The fetus protection effects of Zhixue Baotai Decoction on women of early threatened abortion with dark area surrounding pregnancy sac]. Zhongguo Zhong.Xi.Yi.Jie.He.Za Zhi. 2007;27(11):1025-1028. View abstract.

Steffen, A. M., Thompson, L. W., Gallagher-Thompson, D., and Koin, D. Physical and psychosocial correlates of hormone replacement therapy with chronically stressed postmenopausal women. J.Aging Health 1999;11(1):3-26. View abstract.

Stein, D., Blumensohn, R., and Witztum, E. Perimenstrual psychosis among female adolescents: two case reports and an update of the literature. Int.J.Psychiatry Med. 2003;33(2):169-179. View abstract.

Strohl, K. P., Hensley, M. J., Saunders, N. A., Scharf, S. M., Brown, R., and Ingram, R. H., Jr. Progesterone administration and progressive sleep apneas. JAMA 3-27-1981;245(12):1230-1232. View abstract.

Sumita S, Sofat S Sr. Intramuscular versus intravaginal progesterone as luteal phase and early pregnancy support in patients undergoing IVF-ET [abstract]. Fertility and Sterility 2003;

SWYER, G. I. and DALEY, D. Progesterone implantation in habitual abortion. Br.Med.J. 5-16-1953;1(4819):1073-1077. View abstract.

Taylor, J. W. Plasma progesterone, oestradiol 17 beta and premenstrual symptoms. Acta Psychiatr.Scand. 1979;60(1):76-86. View abstract.

Tognoni, G., Ferrario, L., Inzalaco, M., and Crosignani, P. G. Progestagens in threatened abortion. Lancet 12-6-1980;2(8206):1242-1243. View abstract.

Toh, Y. C., Jain, J., Rahnny, M. H., Bode, F. R., and Ross, D. Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0.65 mL) contraceptive formulation in Asian women. Clin.Ther. 2004;26(11):1845-1854. View abstract.

Torode HW, Porter RN Vaughan JI Saunders DM. Luteal phase support after in vitro fertilisation: a trial and rationale for selective use. Clinical Reproduction and Fertility 1987;5:255-61.

Trotter, A., Maier, L., Grill, H. J., Kohn, T., Heckmann, M., and Pohlandt, F. Effects of postnatal estradiol and progesterone replacement in extremely preterm infants. J.Clin.Endocrinol.Metab 1999;84(12):4531-4535. View abstract.

Trotter, A., Maier, L., Grill, H. J., Wudy, S. A., and Pohlandt, F. 17Beta-estradiol and progesterone supplementation in extremely low-birth-weight infants. Pediatr.Res. 1999;45(4 Pt 1):489-493. View abstract.

Ugur M, Yenicesu O Ozcan S Keles G Gokmen O. A prospective randomized study comparing hCG, vaginalmicronized porgesterone and a combination regimen for luteal phase support in an in-vitro fertilization programme [abstract]. 2001;

Van der Meer YG, Benedek-Jaszmann LJ Van Loenen AC. Effect of high-dose progesterone on the pre-menstrual syndrome: A double-blind cross-over trial. . Journal of Psychosomatic Obstetrics & Gynecology 1983;2(4):220-222.

Van der Meer YG, Loendersloot EW Van Loenen AC. Effect of high-dose progesterone in post-partum depression. Journal of Psychosomatic Obstetrics & Gynecology.1 1984;3(1): 67-68.

Van Steirteghem, A. C., Smitz, J., Camus, M., Van, Waesberghe L., Deschacht, J., Khan, I., Staessen, C., Wisanto, A., Bourgain, C., and Devroey, P. The luteal phase after in-vitro fertilization and related procedures. Hum.Reprod. 1988;3(2):161-164. View abstract.

van Wingen, G. A., van, Broekhoven F., Verkes, R. J., Petersson, K. M., Backstrom, T., Buitelaar, J. K., and Fernandez, G. Progesterone selectively increases amygdala reactivity in women. Mol.Psychiatry 2008;13(3):325-333. View abstract.

van, Broekhoven F., Backstrom, T., and Verkes, R. J. Oral progesterone decreases saccadic eye velocity and increases sedation in women. Psychoneuroendocrinology 2006;31(10):1190-1199. View abstract.

van, Wingen G., van, Broekhoven F., Verkes, R. J., Petersson, K. M., Backstrom, T., Buitelaar, J., and Fernandez, G. How progesterone impairs memory for biologically salient stimuli in healthy young women. J.Neurosci. 10-17-2007;27(42):11416-11423. View abstract.

Vanselow, W., Dennerstein, L., Greenwood, K. M., and de, Lignieres B. Effect of progesterone and its 5 alpha and 5 beta metabolites on symptoms of premenstrual syndrome according to route of administration. J.Psychosom.Obstet.Gynaecol. 1996;17(1):29-38. View abstract.

Vercellini, P., De, Giorgi O., Oldani, S., Cortesi, I., Panazza, S., and Crosignani, P. G. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am.J.Obstet.Gynecol. 1996;175(2):396-401. View abstract.

Vimpeli, T., Tinkanen, H., Huhtala, H., Ronnberg, L., and Kujansuu, E. Salivary and serum progesterone concentrations during two luteal support regimens used in in vitro fertilization treatment. Fertil.Steril. 2001;76(4):847-848. View abstract.

Wahabi, H. A., Abed Althagafi, N. F., and Elawad, M. Progestogen for treating threatened miscarriage. Cochrane.Database.Syst.Rev. 2007;(3):CD005943. View abstract.

Walpurger, V., Pietrowsky, R., Djahansouzi, S., and Wolf, O. T. No changes in event-related potentials with estrogen or estrogen plus progesterone treatment in healthy older hysterectomized women: results from a double-blind, placebo-controlled study. Psychopharmacology (Berl) 2005;179(3):652-661. View abstract.

Wang, X. T. and Johnston, V. S. Changes in cognitive and emotional processing with reproductive status. Brain Behav.Evol. 1993;42(1):39-47. View abstract.

Wegesin, D. J. and Stern, Y. Effects of hormone replacement therapy and aging on cognition: evidence for executive dysfunction. Neuropsychol.Dev.Cogn B Aging Neuropsychol.Cogn 2007;14(3):301-328. View abstract.

Weissbluth, M. and Green, O. C. Plasma progesterone concentrations and infant temperament. J.Dev.Behav.Pediatr. 1984;5(5):251-253. View abstract.

Wentz, A. C., Herbert, C. M., Maxson, W. S., and Garner, C. H. Outcome of progesterone treatment of luteal phase inadequacy. Fertil.Steril. 1984;41(6):856-862. View abstract.

Whitehead, M. I., Townsend, P. T., Gill, D. K., Collins, W. P., and Campbell, S. Absorption and metabolism of oral progesterone. Br.Med.J. 3-22-1980;280(6217):825-827. View abstract.

Wirth, M. M., Meier, E. A., Fredrickson, B. L., and Schultheiss, O. C. Relationship between salivary cortisol and progesterone levels in humans. Biol.Psychol. 2007;74(1):104-107. View abstract.

Wolf, O. T., Heinrich, A. B., Hanstein, B., and Kirschbaum, C. Estradiol or estradiol/progesterone treatment in older women: no strong effects on cognition. Neurobiol.Aging 2005;26(7):1029-1033. View abstract.

Wong, Y. F., Loong, E. P., Mao, K. R., Tam, P. P., Panesar, N. S., Neale, E., and Chang, A. M. Salivary oestradiol and progesterone after in vitro fertilization and embryo transfer using different luteal support regimens. Reprod.Fertil.Dev. 1990;2(4):351-358. View abstract.

Wuttke, W., Arnold, P., Becker, D., Creutzfeldt, O., Langenstein, S., and Tirsch, W. Circulating hormones, EEG, and performance in psychological tests of women with and without oral contraceptives. Psychoneuroendocrinology 1975;1(2):141-151. View abstract.

Yonker, J. E., Adolfsson, R., Eriksson, E., Hellstrand, M., Nilsson, L. G., and Herlitz, A. Verified hormone therapy improves episodic memory performance in healthy postmenopausal women. Neuropsychol.Dev.Cogn B Aging Neuropsychol.Cogn 2006;13(3-4):291-307. View abstract.

Yoon, B. K., Kim, D. K., Kang, Y., Kim, J. W., Shin, M. H., and Na, D. L. Hormone replacement therapy in postmenopausal women with Alzheimer's disease: a randomized, prospective study. Fertil.Steril. 2003;79(2):274-280. View abstract.

Yovich, J. L., Edirisinghe, W. R., and Cummins, J. M. Evaluation of luteal support therapy in a randomized controlled study within a gamete intrafallopian transfer program. Fertil.Steril. 1991;55(1):131-139. View abstract.

Yovich, J. L., Stanger, J. D., Yovich, J. M., and Tuvik, A. I. Assessment and hormonal treatment of the luteal phase of in vitro fertilization cycles. Aust.N.Z.J.Obstet.Gynaecol. 1984;24(2):125-130. View abstract.

Zhang, J., Zhang, Y., and Liu, G. [Clinical and experimental study on yun'an granule in treating threatened abortion]. Zhongguo Zhong.Xi.Yi.Jie.He.Za Zhi. 2000;20(4):251-254. View abstract.

Zweifel, J. E. and O'Brien, W. H. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 1997;22(3):189-212. View abstract.

Affinito P, Di Carlo C, Di Mauro P, et al. Endometrial hyperplasia: efficacy of a new treatment with a vaginal cream containing natural micronized progesterone. Maturitas 1994;20:191-8. View abstract.

Bracco GL, Carli P, Sonni L, et al. Clinical and histologic effects of topical treatments of vulval lichen sclerosus. A critical evaluation. J Reprod Med 1993;38:37-40. View abstract.

Burnham TH, ed. Drug Facts and Comparisons, Updated Monthly. Facts and Comparisons, St. Louis, MO.

Burry KA, Paton PE, Hermsmeyer K. Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen. Am J Obstet Gynecol 1999;180:1504-11. View abstract.

Chen FP, Lee N, Soong YK. Changes in the lipoprotein profile in postmenopausal women receiving hormone replacement therapy. Effects of natural and synthetic progesterone. J Reprod Med 1998;43:568-74. View abstract.

Cooper A, Spencer C, Whitehead MI, et al. Systemic absorption of progesterone cream from Progest cream in postmenopausal women. Lancet 1998;351:1255-6.

Cooper AJ, Whitehead MI. Correspondence. Lancet 1998;352:906.

Damario MA, Goudas VT, Session DR, et al. Crinone 8% vaginal progesterone gel results in lower embryonic implantation efficiency after in vitro fertilization-embryo transfer. Fertil Steril 1999;72:830-6. View abstract.

Darj E, Nilsson S, Axelsson O, et al. Clinical and endometrial effects of oestradiol and progesterone in post-menopausal women. Maturitas 1991;13:109-15. View abstract.

Espeland MA, Hogan PE, Fineberg SE, et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care 1998;21:1589-95. View abstract.

Espeland MA, Marcovina SM, Miller V, et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Circulation 1998;97:979-86. View abstract.

FDA MedWatch. Summary of safety-related drug labeling changes approved by FDA May 1998. Crinone (progesterone) Gel. May 11, 1998. Available at:


FDA. Guide to Inspections of Cosmetic Product Manufacturers: products containing estrogenic hormones, placental extract or vitamins. 2001. Available at:

Fitzpatrick LA, Pace C, Wiita B. Comparison of regimens containing oral micronized progesterone or medroxyprogesterone acetate on quality of life in postmenopausal women: a cross-sectional survey. J Womens Health Gend Based Med 2000;9:381-7. View abstract.

Freeman EW, Rickels K, Sondheimer SJ, Polansky M. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995;274:51-7. View abstract.

Freeman EW, Weinstock L, Rickels K, et al. A placebo-controlled study of effects of oral progesterone on performance and mood. Br J Clin Pharmacol 1992;33:293-8. View abstract.

Gibbons WE, Toner JP, Hamacher P, Kolm P. Experience with a novel vaginal progesterone preparation in a donor oocyte program. Fertil Steril 1998;69:96-101. View abstract.

Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Interventions Trial. Obstet Gynecol 1998;92:982-8. View abstract.

Koh KK, Jin DK, Yang SH, et al. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women. Circulation 2001;103:1961-6. View abstract.

Langer RD. Micronized progesterone: a new therapeutic option. Int J Fertil Womens Med 1999;44:67-73. View abstract.

Lemay A, Dodin S, Kadri N, et al. Flaxseed dietary supplement versus hormone replacement therapy in hypercholesterolemic menopausal women. Obstet Gynecol 2002;100:495-504.. View abstract.

Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999;94:225-8. View abstract.

Licciardi FL, Kwiatkoski A, Noyes NL, et al. Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study. Fertil Steril 1999;71:614-8. View abstract.

Martorano JT, Ahlgrimm M, Colbert T. Differentiating between natural progesterone and synthetic progestins: clinical implications for premenstrual syndrome and perimenopause management. Compr Ther 1998;24:336-9. View abstract.

Miles RA, Paulson RJ, Lobo RA, et al. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 1994;62:485-90. View abstract.

Nappi C, Affinito P, Di Carlo C, et al. Double-blind controlled trial of progesterone vaginal cream treatment for cyclical mastodynia in women with benign breast disease. J Endocrinol Invest 1992;15:801-6. View abstract.

Perino M, Brigandi FG, Abate FG, et al. Intramuscular versus vaginal progesterone in assisted reproduction: a comparative study. Clin Exp Obstet Gynecol 1997;24:228-31. View abstract.

Phy, J. L., Weiss, W. T., Weiler, C. R., and Damario, M. A. Hypersensitivity to progesterone-in-oil after in vitro fertilization and embryo transfer. Fertil Steril 2003;80(5):1272-1275. View abstract.

Pouly JL, Bassil S, Frydman R, et al. Luteal support after in-vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Hum Reprod 1996;11:2085-9. View abstract.

Rosano GM, Webb CM, Chierchia S, et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol 2000;36:2154-9.

Ross D, Cooper AJ, Pryse-Davies J, et al. Randomized, double-blind, dose-ranging study of the endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women. Am J Obstet Gynecol 1997;177:937-41. View abstract.

Schweizer E, Case WG, Garcia-Espana F, et al. Progesterone co-administration in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and taper outcome. Psychopharmacol (Berl) 1995;117:424-9. View abstract.

Smitz J, Devroey P, Faguer B, et al. A prospective randomized comparison of intramuscular or intravaginal natural progesterone as a luteal phase and early pregnancy supplement. Hum Reprod 1992;7:168-75. View abstract.

Veysman, B., Vlahos, I., and Oshva, L. Pneumonitis and eosinophilia after in vitro fertilization treatment. Ann Emerg Med 2006;47(5):472-475. View abstract.

Warren MP, Biller BMK, Shangold MM. A new clinical option for hormone replacement therapy in women with secondary amenorrhea: effects of cyclic administration of progesterone from the sustained-release vaginal gel Crinone (4% and 8%) on endometrial morphologic features and withdrawal bleeding. Am J Obstet Gynecol 1999;180:42-8. View abstract.

Wyatt K, Dimmock P, Jones P, et al. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ 2001;323:776-80.. View abstract.

Young DS. Effects of Drugs on Clinical Laboratory Tests 4th ed. Washington: AACC Press, 1995.

Zorgniotti AW, Lizza EF. Effect of large doses of the nitric oxide precursor, L-arginine, on erectile dysfunction. Int J Impot Res 1994;6:33-5. View abstract.

Health Solutions From Our Sponsors